Clinical Trials
- Brain, Spinal Cord & Nervous System
Identifying and Characterizing Preclinical MS
- Ages13 years and older
- GenderBoth
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive Multiple Sclerosis
- Ages18 years - 60 years
- GenderBoth
- Brain, Spinal Cord & Nervous System
AMS05: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis